Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1979 1
1986 1
1990 1
1996 2
2003 1
2004 2
2005 1
2006 2
2008 1
2009 3
2010 3
2011 3
2012 4
2013 4
2014 4
2015 4
2016 14
2017 12
2018 24
2019 19
2020 32
2021 49
2022 73
2023 89
2024 85
2025 49

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

407 results

Results by year

Filters applied: . Clear all
Page 1
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.
Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, Cosimano MP, Klinedinst MA. Griffiths RR, et al. J Psychopharmacol. 2016 Dec;30(12):1181-1197. doi: 10.1177/0269881116675513. J Psychopharmacol. 2016. PMID: 27909165 Free PMC article. Clinical Trial.
Cancer patients often develop chronic, clinically significant symptoms of depression and anxiety. Previous studies suggest that psilocybin may decrease depression and anxiety in cancer patients. The effects of psilocybin were studied in 51 cancer patie …
Cancer patients often develop chronic, clinically significant symptoms of depression and anxiety. Previous studies suggest that ps …
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.
Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, Mennenga SE, Belser A, Kalliontzi K, Babb J, Su Z, Corby P, Schmidt BL. Ross S, et al. J Psychopharmacol. 2016 Dec;30(12):1165-1180. doi: 10.1177/0269881116675512. J Psychopharmacol. 2016. PMID: 27909164 Free PMC article. Clinical Trial.
Historical and recent research suggests a role for psilocybin to treat cancer-related anxiety and depression. METHODS: In this double-blind, placebo-controlled, crossover trial, 29 patients with cancer-related anxiety and depression were randomly assigned and …
Historical and recent research suggests a role for psilocybin to treat cancer-related anxiety and depression. METHODS: In this …
Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.
Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, Greer GR. Grob CS, et al. Arch Gen Psychiatry. 2011 Jan;68(1):71-8. doi: 10.1001/archgenpsychiatry.2010.116. Epub 2010 Sep 6. Arch Gen Psychiatry. 2011. PMID: 20819978 Clinical Trial.
This investigation reexamines a potentially promising clinical application of hallucinogens in the treatment of anxiety reactive to advanced-stage cancer. OBJECTIVE: To explore the safety and efficacy of psilocybin in patients with advanced-stage cancer and reactive …
This investigation reexamines a potentially promising clinical application of hallucinogens in the treatment of anxiety reactive to a …
The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis.
Goldberg SB, Pace BT, Nicholas CR, Raison CL, Hutson PR. Goldberg SB, et al. Psychiatry Res. 2020 Feb;284:112749. doi: 10.1016/j.psychres.2020.112749. Epub 2020 Jan 2. Psychiatry Res. 2020. PMID: 31931272 Review.
The current meta-analysis examined the effects of psilocybin in combination with behavioral interventions on anxiety and depression in samples with elevated symptoms. ...Results tentatively support future research on psilocybin for the treatment of anxiety …
The current meta-analysis examined the effects of psilocybin in combination with behavioral interventions on anxiety and depre …
The Therapeutic Potential of Psilocybin.
Lowe H, Toyang N, Steele B, Valentine H, Grant J, Ali A, Ngwa W, Gordon L. Lowe H, et al. Molecules. 2021 May 15;26(10):2948. doi: 10.3390/molecules26102948. Molecules. 2021. PMID: 34063505 Free PMC article. Review.
This prohibition on psychedelic drug research significantly delayed advances in medical knowledge on the therapeutic uses of agents such as psilocybin. A 2004 pilot study from the University of California, Los Angeles, exploring the potential of psilocybin treatment …
This prohibition on psychedelic drug research significantly delayed advances in medical knowledge on the therapeutic uses of agents such as …
Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life.
Goodwin GM, Aaronson ST, Alvarez O, Atli M, Bennett JC, Croal M, DeBattista C, Dunlop BW, Feifel D, Hellerstein DJ, Husain MI, Kelly JR, Lennard-Jones MR, Licht RW, Marwood L, Mistry S, Páleníček T, Redjep O, Repantis D, Schoevers RA, Septimus B, Simmons HJ, Soares JC, Somers M, Stansfield SC, Stuart JR, Tadley HH, Thiara NK, Tsai J, Wahba M, Williams S, Winzer RI, Young AH, Young MB, Zisook S, Malievskaia E. Goodwin GM, et al. J Affect Disord. 2023 Apr 14;327:120-127. doi: 10.1016/j.jad.2023.01.108. Epub 2023 Feb 4. J Affect Disord. 2023. PMID: 36740140 Free article. Clinical Trial.
RESULTS: At Week 3, psilocybin 25 mg, compared with 1 mg, was associated with greater improvements from Baseline total scores in all measures. ...LIMITATIONS: Interpretation of this trial is limited by the absence of an active comparator and the possibility of functional u …
RESULTS: At Week 3, psilocybin 25 mg, compared with 1 mg, was associated with greater improvements from Baseline total scores in all …
Psilocybin for Trauma-Related Disorders.
Khan AJ, Bradley E, O'Donovan A, Woolley J. Khan AJ, et al. Curr Top Behav Neurosci. 2022;56:319-332. doi: 10.1007/7854_2022_366. Curr Top Behav Neurosci. 2022. PMID: 35711024 Review.
We provide an overview of trauma and PTSD and cite literature providing converging evidence of the therapeutic potential of psilocybin for PTSD. No study to date has investigated psilocybin or psilocybin-assisted psychotherapy (PAP) as treatments for PTSD. An …
We provide an overview of trauma and PTSD and cite literature providing converging evidence of the therapeutic potential of psilocybin …
Psilocybin: from ancient magic to modern medicine.
Nichols DE. Nichols DE. J Antibiot (Tokyo). 2020 Oct;73(10):679-686. doi: 10.1038/s41429-020-0311-8. Epub 2020 May 12. J Antibiot (Tokyo). 2020. PMID: 32398764 Review.
Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is an indole-based secondary metabolite produced by numerous species of mushrooms. ...In the past 10-15 years several FDA-approved clinical studies have indicated potential medical value for psilocybin-assisted psy …
Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is an indole-based secondary metabolite produced by numerous species of mushrooms …
Update on treatments for anxiety-related disorders.
Lee HJ, Stein MB. Lee HJ, et al. Curr Opin Psychiatry. 2023 Mar 1;36(2):140-145. doi: 10.1097/YCO.0000000000000841. Epub 2022 Dec 6. Curr Opin Psychiatry. 2023. PMID: 36480651 Review.
Other novel products, such as ketamine, psilocybin and cannabidiol, are in the process of gathering evidence in support of the treatment of anxiety disorders. ...SUMMARY: Pharmacotherapy of anxiety disorders is expanding to novel products. Despite trying othe …
Other novel products, such as ketamine, psilocybin and cannabidiol, are in the process of gathering evidence in support of the treatm …
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.
Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, Feilding A, Taylor D, Pilling S, Curran VH, Nutt DJ. Carhart-Harris RL, et al. Lancet Psychiatry. 2016 Jul;3(7):619-27. doi: 10.1016/S2215-0366(16)30065-7. Epub 2016 May 17. Lancet Psychiatry. 2016. PMID: 27210031 Free article. Clinical Trial.
The primary outcome measure for feasibility was patient-reported intensity of psilocybin's effects. Patients were monitored for adverse reactions during the dosing sessions and subsequent clinic and remote follow-up. ...This trial is registered with ISRCTN, number I …
The primary outcome measure for feasibility was patient-reported intensity of psilocybin's effects. Patients were monitored fo …
407 results

Searches related to "psilocybin anxiety"